Constance D. Lehman
Breast radiologist who co-developed the Mirai AI model that predicts breast cancer risk from a mammogram.
Overview
Constance Lehman co-led with Regina Barzilay the development and validation of Mirai, a deep-learning model that predicts five-year breast cancer risk from mammograms more accurately than clinical risk models across diverse populations, and led the ACRIN studies establishing MRI screening of the contralateral breast. She has led national breast imaging quality initiatives and now works on AI-driven personalised screening.
| Title | Journal | Year |
|---|---|---|
| Toward robust mammography-based models for breast cancer risk | Science Translational Medicine | 2021 |
| MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer (ACRIN 6667) | NEJM | 2007 |
Pages like this
not linked directly; found by shared links- PersonKristina Lång
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer and the tags screening, ai, breast.
- TechnologyMirai (MIT breast cancer risk from mammograms)
Shares Massachusetts General Hospital Cancer Center, Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- PersonLecia V. Sequist
Shares Science Translational Medicine, Massachusetts General Hospital Cancer Center, AI in radiology.
- PersonRegina Barzilay
Shares AI in radiology, HR-positive / HER2-negative breast cancer and the tags screening, ai.
- CompanyKheiron Medical Technologies
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyTherapixel
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- CompanyVara
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
- PersonMarcela V. Maus
Shares Science Translational Medicine, Massachusetts General Hospital Cancer Center.